MEDiC Life Sciences
MEDIC Life Sciences is dedicated to revolutionizing cancer drug development through its proprietary CRISPR functional genomics platform in 3D tumor models. The company aims to systematically discover biomarkers, synthetic lethality, resistant mutations, and novel drug targets for cancer, leveraging its unique tumor-immune co-culture system integrated with CRISPR technology. With a focus on precision medicine, MEDIC Life Sciences collaborates with industry partners to develop first-in-class oncology drugs and identify biomarkers linked to drug resistance, ultimately improving patient stratification and treatment outcomes.
Industries
Nr. of Employees
small (1-50)
MEDiC Life Sciences
San Carlos, California, United States, North America
Products
Integrated CRISPR functional-genomics and 3D tumor screening platform
An experimental platform combining genome-scale CRISPR perturbations, three-dimensional patient-like tumor/spheroid cultures, immune co-culture, and NGS readouts to identify targets, biomarkers, and resistance mechanisms.
Integrated CRISPR functional-genomics and 3D tumor screening platform
An experimental platform combining genome-scale CRISPR perturbations, three-dimensional patient-like tumor/spheroid cultures, immune co-culture, and NGS readouts to identify targets, biomarkers, and resistance mechanisms.
Services
Functional-genomics screening service in 3D tumor models
End-to-end execution of genome-wide CRISPR screens in three-dimensional tumor spheroids/organoids to identify genes impacting growth, drug sensitivity, and resistance.
Tumor–immune co-culture screening service
Assays combining patient-like 3D tumor models with human T cells to evaluate immune-modulatory effects of genetic perturbations and to discover immuno-oncology targets or biomarkers.
High-throughput sequencing and genomic data services
Generation and processing of large-scale sequencing datasets from screened models to support readout of pooled CRISPR experiments and downstream biomarker analyses.
Collaborative target/biomarker co-development
Partnership programs to apply platform capabilities toward co-development of first-in-class oncology drugs or identification of biomarkers for existing therapeutic assets.
Functional-genomics screening service in 3D tumor models
End-to-end execution of genome-wide CRISPR screens in three-dimensional tumor spheroids/organoids to identify genes impacting growth, drug sensitivity, and resistance.
Tumor–immune co-culture screening service
Assays combining patient-like 3D tumor models with human T cells to evaluate immune-modulatory effects of genetic perturbations and to discover immuno-oncology targets or biomarkers.
High-throughput sequencing and genomic data services
Generation and processing of large-scale sequencing datasets from screened models to support readout of pooled CRISPR experiments and downstream biomarker analyses.
Collaborative target/biomarker co-development
Partnership programs to apply platform capabilities toward co-development of first-in-class oncology drugs or identification of biomarkers for existing therapeutic assets.
Expertise Areas
- Functional genomics screening
- 3D tumor and organoid modeling
- Immuno-oncology target discovery
- Biomarker and resistance mutation discovery
Key Technologies
- CRISPR-based genome-wide screening
- Next-generation sequencing (NGS)
- 3D spheroid/organoid culture
- Tumor–immune co-culture assays